FDA Drug Approval Summaries: Oxaliplatin

FDA Drug Approval Summaries: Oxaliplatin Amna Ibrahim, Steven Hirschfeld, Martin H. Cohen, Donna J. Griebel, Grant A. Williams, Richard Pazdur Oncologist 2004; 9: 8-12 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine and FDA information, and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the safe and effective use of oxaliplatin in patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first-line therapy with the combination of bolus 5-FU/LV and irinotecan. List the major common toxicities of oxaliplatin. Discuss the limitations of the results of the reviewed trial. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 30, 2004 Most Recent Review: Jan. 30, 2004* Most Recent Update: Jan. 30, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.